Drug Trial Radar · NCT06346340
A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy
Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
97
Actual
Start
Apr 30, 2024
Primary completion
Feb 24, 2025
Study completion Feb 24, 2025
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Apr 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 4, Multicenter, Open-Label Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/ Keratometry and Postoperative Refractive Accuracy
Conditions
- Dry Eye
Interventions
MieboDrug
Miebo applied in both eyes 4 times per day for approximately 30 days before cataract surgery. Following the completion of the standard follow up, approximately 30 days after cataract surgery, subjects will begin a second regimen of Miebo , 4 times per day in both eyes, for approximately 30 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Difference Between Absolute Deviations From Predicted Refractive Error in the Study Eye.Time frame: Assessed at Postop Day 30 ± 7 days
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Site 105
Laguna Hills, California
Site 102
Petaluma, California
Site 109
Sacramento, California
Site 111
Grand Junction, Colorado
Site 103
Largo, Florida
Site 106
Oak Lawn, Illinois
Site 108
Alexandria, Minnesota
Site 104
St Louis, Missouri
Site 101
Somersworth, New Hampshire
Site 107
Sioux Falls, South Dakota
Site 110
San Antonio, Texas
Site 112
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.